Table 3.
Inhibitor drugs under clinical studies for neuroblastoma treatment are reported (ClinicalTrials.Gov, updated 1 August 2022). Drug inhibitor target, clinical phases, trial status and ID are reported.
| Drug Name | Target | Clinical Phase | Status | NTC Number |
|---|---|---|---|---|
| Vorinostat | HDAC | Phase1|Phase2 | Recruiting|Completed|No longer available | NCT01019850|NCT03561259|NCT01838187|NCT01132911|NCT02559778|NCT03332667|NCT02035137|NCT01208454|NCT04308330 |
| Panobinostat | HDAC | Phase 2 | Terminated | NCT04897880 |
| BMS-986158 | BET | Phase 1 | Recruiting | NCT03936465 |
| BMS-986378 | BET | Phase1 | Recruiting | NCT03936465 |
| GSK525762 | BET | Phase1 | Completed | NCT01587703 |
| SF1126 | PI3K/mTOR | Phase 1 | Terminated | NCT02337309 |
| Samotolisib | PI3K/mTOR | Phase 2 | Recruiting | NCT03213678 |
| ALRN-6924 | Dual MDM2/MDMX | Phase 1 | Recruiting | NCT03654716 |
| LY3295668 | Aurora-A Kinase | Phase 1 | Active, no recruiting | NCT04106219 |
| Alisertib (MLN8237) | Aurora-A Kinase | Phase 1|Phase 2 | Complete | NCT02444884|NCT01601535|NCT01154816 |
Abbreviation: HDAC, histone deacetylase; BET, bromodomain and extra-terminal motif; PI3K Phosphoinositide 3-kinases; mTOR, mechanistic target of rapamycin.